Last reviewed · How we verify
Intermittent dosing of AZD5363 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intermittent dosing of AZD5363 (Intermittent dosing of AZD5363) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intermittent dosing of AZD5363 TARGET | Intermittent dosing of AZD5363 | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intermittent dosing of AZD5363 CI watch — RSS
- Intermittent dosing of AZD5363 CI watch — Atom
- Intermittent dosing of AZD5363 CI watch — JSON
- Intermittent dosing of AZD5363 alone — RSS
Cite this brief
Drug Landscape (2026). Intermittent dosing of AZD5363 — Competitive Intelligence Brief. https://druglandscape.com/ci/intermittent-dosing-of-azd5363. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab